Feedback / Questions
ralpancizumab (RN317) - Pfizer
Pfizer pipeline
(Pfizer Press Release)
-
Feb 28, 2014 -
RN317 (PF-05335810) discontinued from development for Hyperlipidemia since November 8, 2013.
Discontinued
•
Atherosclerosis • Dyslipidemia
http://www.pfizer.com/sites/default/files/product-pipeline/BT_February%2028%2C%202014%20Pipeline%20Update_28Feb14.pdf
Feb 28, 2014
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious